Global Oral Drug Delivery Technology Market Size & Trends Report Segmented by Dosage Form (Solid, Tablets, Capsules, Liquid, Gels), Delivery (Conventional, Controlled-release), Application (Oncology, CVDs, GI, CNS), End-user (Hospitals/Clinics, ASCs), & Regional Forecast to 2031

Oral Drug Delivery Technology refers to the formulation approaches and delivery systems designed to administer therapeutic agents through the mouth for absorption via the gastrointestinal tract or oral mucosa. They consist of tablets, capsules, oral films, liquid formulations, and advanced systems such as controlled release, targeted release, and nanoparticle-based oral drug delivery systems among others. Oral drug delivery technology improves the stability, solubility, bioavailability, and effectiveness of medication while enabling easy and non-invasive administration. There is a high preference for using oral delivery as it provides a convenient way for patients to take their medications, improve compliance, and reduce healthcare costs. The advanced oral drug delivery technologies also produce modified release profiles, site specific absorption, and better delivery of complex molecules. All these attributes facilitate better outcomes for patients suffering from chronic and acute diseases.

High patient compliance, convenience, and non-invasive nature to propel market demand

High patient compliance, convenience, and the non-invasive nature of oral drug delivery are among the most important factors driving the growth of the oral drug delivery technology market. Patients favor oral delivery methods, such as pills, tablets, and capsules, over those using other complicated routes, such as injections or other invasive methods, as these methods are less painful, more comfortable, and less stressful than injectables. In turn, this leads to improved adherence to treatment regimens in patients who require chronic or long-term use of medication for diseases that require life-long treatment, such as diabetes; cardiovascular disorders; neurological conditions; and cancer. When patients are more willing to take medications consistently their medications lead to better therapeutic outcomes. Therefore, oral delivery is the preferred method for pharmaceutical companies to use when delivering a medication whenever possible.

Other significant benefit of using oral routes to administer is that it is more convenient than other means. Oral medications can be self-administered without the use of trained healthcare personnel or expensive equipment, as compared to other routes. Therefore, patients may not need to visit hospitals regularly for delivery of medication. This is important for elderly patients, mobility impaired individuals, or individuals living in isolated areas or low resource communities, and for patients who may have limited options for transportation to a hospital or clinic. In addition to being simple to work with, oral administration also supports outpatient care models, and allows for healthcare systems to reduce both their operational costs and the amount of clinical activity occurring within a clinical practice.

Oral administration is the method of drugs that makes it less intimidating to patients, particularly when they are receiving medications in a preventative or long-term maintenance therapy that needs to be given over a long period of time at regular intervals. The likelihood of a patient following through with their medications given daily by mouth rather than the number of times they could receive injections may lead to more effective management of a chronic illness without complications. This is particularly important in large patient populations with chronic diseases, where long-term adherence directly impacts healthcare outcomes and costs.

Due to strong patient preference for oral dosage form of medication, many pharmaceutical companies are now investing into developing more advanced oral drug delivery technologies like, controlled-release formulations, orally disintegrating tablets, and gastro-retentive systems, among others, which need less frequent dosing, easier swallowing and better absorption of drugs that can improve the overall patient experience with these more advanced forms of oral drug delivery. The recent shift towards more patient-centered healthcare is placing greater importance on convenience and adherence for both drug manufacturers and healthcare professionals in their formulary decision-making processes. Therefore, with both patient preference and healthcare system emphasize on convenience and adherence as the two major influences driving innovation, and ultimately expanding the use of more advanced forms of oral drug delivery technology within therapeutic areas.

To learn more about this report, download the PDF brochure

Technological advancements in controlled and targeted drug delivery are driving the market growth

Technological advancements in controlled and targeted drug delivery are playing a critical role in driving the growth of the oral drug delivery technology market by improving therapeutic effectiveness, safety, and patient convenience. Conventional oral formulations often release drugs immediately after administration, which can result in fluctuating drug concentrations in the bloodstream, reduced efficacy, and increased risk of adverse effects. Controlled-release technologies such as sustained-release, extended-release, and delayed-release allow the medications to be released in a controlled manner over a fixed period of time. This way the therapeutic levels in the body can be maintained at a constant level over the course of therapy and the number of times a patient must take medications can be reduced. This is especially important for patients with chronic conditions such as cardiovascular disease, diabetes, and neurological disorders.

Targeted oral drug delivery technologies are also advancing significantly, resulting in the ability of medications to be delivered to specific areas in the gastrointestinal tract. For instance, the use of enteric-coated and colon-targeted delivery systems provides protection to medications from being broken down in the acidic environment of the stomach so that they can be released into the intestine and colon where absorption of medication is most effective. This is especially beneficial for medications that are sensitive to the conditions in the stomach or for the treatment of diseases localized in the intestine, such as inflammatory bowel disease or colorectal cancer. Site-specific delivery improves the bioavailability of medications and reduce the amount of medication in the systemic circulation thus minimizing the adverse effects of medications and improving the overall therapeutic effect of medications. Reflecting these advancements, in October 2024, Evonik Industries AG launched the EUDRACAP preclinic enteric functional oral capsule to streamline preclinical drug development and enable seamless transition from preclinical to clinical and commercial stages using its EUDRACAP platform.

The use of nanotechnological oral delivery systems is also expected to expand the capabilities of oral drug delivery, particularly through polymeric nanoparticles, lipid-based carriers, and nanoemulsions. By enhancing absorption and protecting drugs from enzymatic degradation, the delivery of complex molecules by oral means can be feasible as opposed to injectables. Supporting this advancement, in February 2024, Aston University, University of Nottingham, and King’s College London received US$2.3 million (£1.7 million) funding to develop bioinspired artificial nanoparticles enabling oral delivery of nucleic acid-based therapeutics.

The use of mucoadhesive formulations and gastro-retentive systems prolong the residence time of drugs in the gastrointestinal tract when taken orally resulting in improved absorption and efficacy of the drug through an extended residence time. Pharmaceutical manufacturers are beginning to use these technologies to extend product lifecycles, differentiate branded drug products, and improve the clinical results of their products to give them a competitive advantage. Therefore, technological advances in controlled and targeted oral delivery are paving the way to have more effective treatments, increase the array of available orally administered therapies, and continue the growth and innovation of the oral drug delivery technology market.

To learn more about this report, download the PDF brochure

Dosage Form Segment Outlook

Solid oral dosage forms represent the largest segment of the oral drug delivery market. The reasons for their larger share are their widespread use, relative stability, low cost of manufacture, convenience, and ease of patient acceptance. Tablets and capsules are the most common types of solid oral dosage forms prescribed by healthcare providers worldwide, particularly for the long-term management of chronic disease. This contributes to the larger share of solid oral dosage forms in this market. The fastest-growing segment in the oral drug delivery market is liquid oral dosage forms, driven mainly by the demand from pediatric and geriatric patient populations who cannot swallow solid oral dosage forms safely or easily. In addition, the increased development of oral solutions and suspensions designed for precise dosing, enhanced bioavailability, and personalized therapies has contributed to the rapid growth of this segment. The market for semi-solid oral dosage forms is smaller than that of solid or liquid oral dosage forms as the therapeutic applications of semi-solid dosage forms are limited compared to other types of oral dosage forms.

Regional Outlook: Advanced healthcare infrastructure and strong pharmaceutical innovation position North America as the leading regional market

North America held the largest share of the oral drug-delivery technology market due to its well-established health care system, the high number of pharmaceutical companies, innovations in drug delivery technology and the level of funding for R&D. The prevalence of chronic diseases and the supportive regulatory environments are also positively contributing to the region’s larger share of the market. The Asia Pacific region is expected to register the fastest growth because of improving healthcare access, the large population size, the large number of people with chronic diseases, the rapid growth of pharmaceutical manufacturing in the countries of China and India, government-backed initiatives, and the increasing demand for lower-priced oral therapies have all helped to support the growth across this region.

Competitive Landscape Analysis

The global oral drug delivery technology market is marked by the presence of established and emerging market players such as Johnson & Johnson (US); GSK plc (UK); Pfizer Inc. (US); AstraZeneca (UK); Novartis AG (Switzerland); AbbVie Inc. (US); Sanofi (France); Bristol Myers Squibb (BMS) (US); Eli Lilly and Company (US); and Boehringer Ingelheim International GmbH (Germany); among others. Some of the key strategies adopted by market players include new product launch and approvals, acquisitions, and strategic partnerships, agreements, and collaborations.

Get a sample report for competitive landscape analysis

Growth strategies adopted by players to establish their foothold in the market

Players operating in this market are adopting various growth strategies such as new product launch and approvals; acquisitions; and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

• In February 2026, Novo Nordisk committed up to $2.1 billion to partner with Vivtex to develop advanced oral drug delivery technologies for metabolic disease therapies, particularly peptide-based drugs. The collaboration uses AI-driven screening and gastrointestinal tissue models to improve intestinal absorption, bioavailability, and dosing convenience of orally administered peptide medicines
• In February 2026, Eton Pharmaceuticals received USFDA approval for Desmoda, the first ready-to-use oral liquid desmopressin formulation for treating central diabetes insipidus across all age groups. The oral liquid formulation enables precise, individualized dosing and improves administration convenience compared to traditional tablets, highlighting advancements in patient-friendly oral drug delivery systems
• In August 2025, BioMed X and Novo Nordisk launched a research collaboration to develop innovative oral formulation technologies for peptide drugs such as GLP-1 receptor agonists. The project focuses on enabling site-specific and prolonged retention of oral peptide formulations in the intestine to improve absorption, bioavailability, and patient compliance
• In January 2025, Spektus Pharma and Recipharm announced a strategic partnership to develop CNS therapies using the Flexitab oral drug delivery platform, which enables breakable extended-release tablets for personalized dosing. The platform allows controlled drug release even when tablets are split, improving dosing flexibility, treatment tolerability, and patient-centric oral drug delivery for conditions such as depression and anxiety
• In April 2023, DifGen Pharmaceuticals acquired Aveva Drug Delivery Services to expand its capabilities in complex drug delivery technologies, including oral dissolvable films, strengthening its development and manufacturing capacity for differentiated oral dosage forms

Report Scope

Global Oral Drug Delivery Technology Market Segmentation

This report by Medi-Tech Insights provides the size of the global oral drug delivery technology market at the regional- and country-level from 2024 to 2031. The report further segments the market based on dosage form, delivery type, therapeutic application, and end user.

Market Size & Forecast (2024-2031), By Dosage Form, USD Billion

• Solid Oral Dosage Forms
  • Tablets
  • Capsules
  • Powders and Granules
  • Other Solid Oral Dosage Forms
• Liquid Oral Dosage Forms
  • Syrups
  • Suspensions
  • Solutions
  • Other Liquid Oral Dosage Forms
• Semi-solid Oral Dosage Forms
  • Oral Gels
  • Oral Pastes
• Other Dosage Forms

Market Size & Forecast (2024-2031), By Delivery Type, USD Billion

• Conventional Drug Delivery
• Controlled-release Drug Delivery
• Other Delivery Types

Market Size & Forecast (2024-2031), By Therapeutic Application, USD Billion

• Oncology
• Cardiovascular Diseases (CVDs)
• Diabetes
• Central Nervous System (CNS) Disorders
• Gastrointestinal (GI) Disorders
• Infectious Diseases
• Respiratory Diseases
• Autoimmune Diseases
• Other Therapeutic Applications

Market Size & Forecast (2024-2031), By End User, USD Billion

• Hospitals & Clinics
• Ambulatory Surgical Centers (ASCs)
• Home Care Settings
• Other End Users

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Reports

Global Injectable Drug Delivery Market Report Segmented by Device Type (Conventional & Self-Injectables, Needle-free Injectors), Route of Administration (Intravenous, Subcutaneous, Intramuscular), Therapeutic Application, Formulation Packaging, Forecast to 2031

Global Drug Device Combination Products Market Size & Trends Report Segmented by Product (Transdermal Patches, Infusion Pumps, Inhalers), Application (CVDs, Diabetes, Respiratory Disorders, Oncology), End-user Analysis & Regional Forecast to 2031

Global Pharmaceutical Excipients Market Size & Trends Report Segmented by Product (Alcohols, Polymers, Others), Formulation (Oral, Topical, Parenteral, Others), Function (Fillers & Diluents, Coating Agents, Binders, Others) & Regional Forecast to 2030